Nasal high flow reduces hypercapnia by clearance of anatomical dead space in a COPD patient  by Fricke, Kathrin et al.
lable at ScienceDirect
Respiratory Medicine Case Reports 19 (2016) 115e117Contents lists avaiRespiratory Medicine Case Reports
journal homepage: www.elsevier .com/locate/rmcrCase reportNasal high ﬂow reduces hypercapnia by clearance of anatomical dead
space in a COPD patient
Kathrin Fricke*, Stanislav Tatkov, Ulrike Domanski, Karl-Josef Franke, Georg Nilius,
Hartmut Schneidera r t i c l e i n f o
Article history:
Received 7 June 2016
Received in revised form
22 August 2016
Accepted 24 August 2016
Keywords:
Chronic obstructive pulmonary disease
Nasal high ﬂow
Hypercapnic respiratory failure
Dead space ventilation* Corresponding author.
E-mail address: kfricke1@jhmi.edu (K. Fricke).
http://dx.doi.org/10.1016/j.rmcr.2016.08.010
2213-0071/© 2016 The Authors. Published by Elseviera b s t r a c t
Chronic obstructive pulmonary disease (COPD) with hypercapnia is associated with increased mortality.
Non-invasive ventilation (NIV) can lower hypercapnia and ventilator loads but is hampered by a low
adherence rate leaving a majority of patients insufﬁciently treated.
Recently, nasal high ﬂow (NHF) has been introduced in the acute setting in adults, too. It is an open
nasal cannula system for delivering warm and humidiﬁed air or oxygen at high ﬂow rates (2e50 L/min)
assisting ventilation. It was shown that this treatment can improve hypercapnia. The mechanism of
reducing arterial carbon dioxide (CO2) is proposed through a reduction in nasal dead space ventilation,
but there are no studies in which dead space volume was measured in spontaneously breathing subjects.
In our case report we measured in a tracheostomized COPD patient CO2 and pressure via sealed ports in
the tracheostomy cap and monitored transcutaneous CO2 and tidal volumes. NHF (30 L/min mixed with 3
L/min oxygen) was administered repeatedly at 15-minutes intervals. Inspired CO2 decreased instantly
with onset of NHF, followed by a reduction in transcutaneous/arterial CO2. Minute ventilation on nasal
high ﬂow was also reduced by 700 ml, indicating that nasal high ﬂow led to a reduction of dead space
ventilation thereby improving alveolar ventilation.
In conclusion, NHF assist ventilation through clearance of anatomical dead space, which improves
alveolar ventilation. Since the reduction in hypercapnia was similar to that reported with effective NIV
treatment NHF may become an alternative to NIV in hypercapnic respiratory failure.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
An open nasal cannula system for delivering warm and hu-
midiﬁed air or oxygen at higher ﬂow rates (nasal high ﬂow (NHF),
2e50 L/min) has been shown to assist ventilation and outcomes in
the acute setting in adults and in children. Recently, NHF has been
introduced for respiratory support in ICU settings, mainly in pa-
tients with acute hypoxemic respiratory failure [3,6,12], but some
demonstrating an improvement in hypercapnia and clinical out-
comes, too [6,10,11]. The mechanisms of reducing arterial CO2 is
proposed through a reduction in nasal dead space ventilation [8,9],
but there are no studies in spontaneously breathing subjects. We
therefore, measured tracheal CO2 on and off NHF in a spontane-
ously breathing patient with tracheostomy.
2. Case presentation
A 62-year-old man (smoker, 60 pack years) with severe chronic
obstructive pulmonary disease (COPD GOLD IV) (FEV1: 0,8 L/min),Ltd. This is an open access article ucachexia (BMI 19,8 kg/m2), oxygen dependency (2L/min) and hy-
percapnic respiratory failure with arterial CO2 ranging from 65 to
75 mmHg was studied during wake. His current illness included
critical illness polyneuro- and myopathie after he developed an
acute exacerbation of COPD and was ventilated through a trache-
ostomy for 1 month. He regained muscle strength after neurolog-
ical rehabilitation and was admitted to our pulmonary
rehabilitation unit for considering decannulation of his tracheos-
tomy tube. At the time of this study, his tracheostomy was capped
with a tracheostomy button for several days and he was able to
breathe spontaneously at rest during the day and continued non-
invasive ventilation (NIV) with following settings: Spontaneous/
Timed (S/T)-mode, inspiratory pressure 25 cmH2O, expiratory
pressure 5 cm H2O, backup rate 15/min.3. Methods
The patient was instrumented with intra-tracheal catheters for
CO2 and pressure (PTRACH) measurements via sealed ports in the
tracheostomy cap (Fig. 1). Tidal volume (VT) was measured bynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
K. Fricke et al. / Respiratory Medicine Case Reports 19 (2016) 115e117116respiratory inductive plethysmography (RIP) and arterial CO2 was
monitored transcutaneously (tc CO2). Inspired CO2 was calculated
from the tidal CO2 tracing and tidal volume using the modiﬁed
Fowler technique as previously described [2,4]. The study was per-
formed while the patient was resting in a sitting semi-recumbent
position breathing effortless with 2 L/min oxygen (baseline). Nasal
high ﬂow (NHF 30 L/min mixed with 3 L/min O2 to match his FIO2
requirements)was administered repeatedlyat 15-minutes intervals.
Due to the higher inspiratory ﬂow with NHF a higher oxygen con-
centration (3L/min) is required to achieve the same FIO2.Fig. 2. Increase in tracheal pressure (PTRACH) due to NHF was associated with a
decrease in transcutaneous (Tc) CO2 and inspired (in) CO2 while respiratory rate was
reduced. Tracheal pressure (PTRACH), end-tidal CO2 (ET CO2), tidal volume (VT), trans-
cutaneous CO2 (TcCO2), inspired CO2, (inCO2).4. Results
The effects of NHF on ventilation and arterial blood gases
compared to oxygen are shown in Fig. 2. The top panel shows a 25
minute overview of experimental setup: tracheal pressure (PTRACH),
end tidal tracheal CO2 (ET CO2), tidal volume (VT), transcutaneous
CO2 (Tc CO2), inspired CO2, (in CO2). Grey bars highlight snapshots
of 40 seconds at baseline (left lower panel) and NHF (right lower
panel). As can be seen, NHF increased end-expiratory pressure
(PEEP) by 1 cm H2O, reduced inspiratory CO2 from 6 ± 1 to 3 ± 0,5
ml, and tcCO2 from 68 to 63 mmHg. The reduction in inCO2
occurred instantly with onset of NHF (see vertical arrow in Fig. 2
upper panel) when tcCO2 remained unchanged. While tidal vol-
ume remained similar at 290 ± 15 ml, there was a reduction in
respiratory rate from 26/min to 22/min leading to a reduction in
minute ventilation from 7,2e6.5 L/min (by 700 ml). Based on the
mass balance equation shown below, a reduction in minute venti-
lation (VE) should have increased arterial CO2. Rather, we show a
decrease in tcCO2, which can only be explained by a reduction in
dead space ventilation (VD) exceeding 700 ml/min. Given a respi-
ratory rate of 22/min the NHF must have led to a reduction in dead
space ventilation (VD) of more than 30 mls per breath.5. Summary and interpretation
We assume that the reduction in inspired CO2 by 50% is likely
due to a washout in CO2 of the upper airway for the following
reasons: A) it occurred instantly with onset of NHF when tcCO2
remained unchanged. B) the patient reduced minute ventilation on
NHF by 700 ml/min and tcCO2 decreased which can only be
explained by a reduction in dead space ventilation (VD) exceedingFig. 1. View of study setting: intra-tracheal catheters for CO2 and pressure (PTRACH)
measurements, tidal volume (VT) was measured by respiratory inductive plethys-
mography (RIP) and CO2 was monitored transcutaneously (tcCO2). High ﬂow was
delivered via nasal cannula.700 ml/min based on the mass balance equation. This reduction
was sufﬁcient to reduce ventilatory loads as best documented by a
concomitant ~20% reduction in respiratory rate.
We also show, that in our patient, transcutaneous (arterial) CO2
was lowered by 7.4% with NHF. If this reduction would remain over
an extended period, e.g., sleep, this magnitude of CO2 reduction
would be similar to that using non-invasive ventilation via nasal or
full face mask [5,7].
6. Clinical implications
COPD with hypercapnia is associated with increased mortality
[1] and current treatment options to lower hypercapnia and venti-
latory loads require extensive treatment with invasive or non-
invasive ventilator support [5]. Our data suggest that NHF could be
used as an alternative option to lower arterial CO2 in a subset of
patients. Moreover, the clearance of anatomical dead space by NHF
may be especially beneﬁcial for subjects who have high dead space
ventilation due to tachypnea or due to rapid shallow breathing
pattern as in our patient. Even a small reduction of dead spacewould
lead to a relativelyhigh increase in alveolar volume, since the ratio of
dead space to tidal volume increases during shallow breathing.
In conclusion, NHF can treat hypercapnic respiratory failure in
some patients through clearance of anatomical dead space, which
improvesalveolarventilation, thus leading toreductionofarterialCO2.
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